WEKO3
アイテム
{"_buckets": {"deposit": "9e2c927b-baef-4d98-be42-aa29f6919509"}, "_deposit": {"created_by": 1, "id": "72716", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "72716"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00072716", "sets": ["28"]}, "author_link": ["716242", "716243"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2017-02-15", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background and Aims: 11C-PBB3 is a tau PET ligand that can visualize diverse tau pathologies including Alzheimer’s disease (AD), non-AD tauopathies, and tau transgenic mice. We have developed a 18F-labeled PBB3 derivative, 18F-PM-PBB3. To evaluate the potential utility of this ligand in clinical trials of tau targeting agents, we conducted preclinical and clinical studies using 18F-PM-PBB3.\nMethods: Preclinical characterization of 18F-PM-PBB3 was performed using brain samples of humans and model mice. To perform head-to-head comparison between 18F-PM-PBB3 and 11C-PBB3, patients with AD and progressive supranuclear palsy (PSP), and cognitively healthy subjects underwent PET scans with 18F-PM-PBB3 and 11C-PBB3.\nResults: Preclinical evaluations demonstrated that 18F-PM-PBB3 can bind diverse tau pathologies, including AD, PSP, corticobasal degeneration and Pick’s disease, with high sensitivity and specificity. In clinical PET study, dynamic ranges of 18F-PM-PBB3 yield about 2-fold higher than 11C-PBB3 in visualizing tau lesions, while distribution patterns of specific binding are similar. 18F-PM-PBB3 does not produce prominent off-target signals in basal ganglia. Standardized uptake value ratios can be used as robust and simplified indices of the specific binding.\nConclusions: 18F-PM-PBB3 is a promising PET ligand for quantifying tau pathologies in AD and non-AD patients with suitable pharmacokinetics and high contrast.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "13th Annual Biomarkers Congress", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "島田, 斉"}], "nameIdentifiers": [{"nameIdentifier": "716242", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "島田 斉", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "716243", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Potential utility of novel tau PET ligand, 18F-PM-PBB3", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Potential utility of novel tau PET ligand, 18F-PM-PBB3"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/72716", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-03-22"}, "publish_date": "2018-03-22", "publish_status": "0", "recid": "72716", "relation": {}, "relation_version_is_last": true, "title": ["Potential utility of novel tau PET ligand, 18F-PM-PBB3"], "weko_shared_id": -1}
Potential utility of novel tau PET ligand, 18F-PM-PBB3
https://repo.qst.go.jp/records/72716
https://repo.qst.go.jp/records/72716f378e698-3003-4f53-9d8a-181dc2b2c2b0
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-03-22 | |||||
タイトル | ||||||
タイトル | Potential utility of novel tau PET ligand, 18F-PM-PBB3 | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
島田, 斉
× 島田, 斉× 島田 斉 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background and Aims: 11C-PBB3 is a tau PET ligand that can visualize diverse tau pathologies including Alzheimer’s disease (AD), non-AD tauopathies, and tau transgenic mice. We have developed a 18F-labeled PBB3 derivative, 18F-PM-PBB3. To evaluate the potential utility of this ligand in clinical trials of tau targeting agents, we conducted preclinical and clinical studies using 18F-PM-PBB3. Methods: Preclinical characterization of 18F-PM-PBB3 was performed using brain samples of humans and model mice. To perform head-to-head comparison between 18F-PM-PBB3 and 11C-PBB3, patients with AD and progressive supranuclear palsy (PSP), and cognitively healthy subjects underwent PET scans with 18F-PM-PBB3 and 11C-PBB3. Results: Preclinical evaluations demonstrated that 18F-PM-PBB3 can bind diverse tau pathologies, including AD, PSP, corticobasal degeneration and Pick’s disease, with high sensitivity and specificity. In clinical PET study, dynamic ranges of 18F-PM-PBB3 yield about 2-fold higher than 11C-PBB3 in visualizing tau lesions, while distribution patterns of specific binding are similar. 18F-PM-PBB3 does not produce prominent off-target signals in basal ganglia. Standardized uptake value ratios can be used as robust and simplified indices of the specific binding. Conclusions: 18F-PM-PBB3 is a promising PET ligand for quantifying tau pathologies in AD and non-AD patients with suitable pharmacokinetics and high contrast. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 13th Annual Biomarkers Congress | |||||
発表年月日 | ||||||
日付 | 2017-02-15 | |||||
日付タイプ | Issued |